Medicus Pharma (MDCX)
Develops clinical-stage therapies for skin cancer, urology, oncology, and women’s health.
Medicus Pharma advances pipeline during Q2 with key milestones
Medicus Pharma (NASDAQ:MDCX) has reported second quarter financial results and regulatory and clinical progress across its SkinJect and Teverelix programs, while raising about $40 million through equity and debt financing during the first half of 2026. The company said it received FDA “Study May Proceed” authorization for its registrational SkinJect study in patients with Gorlin Syndrome.
Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Company Highlights Significant Regulatory, Clinical and Strategic Progress Across SkinJect® and Teverelix® Programs and a Strengthened Financial Position Supporting Continued Pipeline Execution and Expansion PHILADELPHIA, PA / ACCESS Newswire / August 12, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today reported financial results for the three and six months ended June 30, 2026, and provided a corporate update highlighting significant regulatory, clinical and strategic achievements across its development portfolio.
Medicus Pharma CMO to lead Antev's Teverelix clinical programme
Medicus Pharma (NASDAQ:MDCX) announced it has put its chief medical officer in charge of UK subsidiary Antev Limited, consolidating leadership of the Teverelix clinical programme ahead of regulatory, late-stage development and partnering work. Dr Faisal Mehmud will become Antev's chief executive on August 30, while retaining his positions as Medicus chief medical officer and co-chairman of the subsidiary.
Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom
Dr. Mehmud's appointment further aligns the scientific, clinical, regulatory and operational leadership of Antev Dr. Mehmud's appointment further aligns the scientific, clinical, regulatory and operational leadership of Antev
Medicus Pharma targets Gorlin Syndrome with SkinJect - ICYMI
Medicus Pharma (NASDAQ:MDCX) earlier this week announced that the US Food and Drug Administration (FDA) has cleared the company's Phase 2b registration-enabling clinical trial for SkinJect in patients with Gorlin syndrome, representing an important regulatory milestone for its lead investigational asset. Speaking with Proactive, CEO Raza Bokhari said the FDA had approved the company's proposed study following discussions and feedback, allowing Medicus Pharma (NASDAQ:MDCX) to move ahead with a crossover registration study involving up to 50 patients.
Medicus Pharma targets Gorlin Syndrome with SkinJect - ICYMI
Medicus Pharma (NASDAQ:MDCX) earlier this week announced that the US Food and Drug Administration (FDA) has cleared the company's Phase 2b...
Medicus Pharma receives UAE authorization for Phase 2a endometriosis study of Teverelix
Medicus Pharma (NASDAQ:MDCX) announced that the United Arab Emirates Department of Health – Abu Dhabi (DOH) has granted Investigational New Drug (IND) authorization for its Phase 2a PRECISION-E2 clinical study evaluating Teverelix in women with moderate-to-severe symptomatic endometriosis. The authorization follows the DOH's review of the company's chemistry, manufacturing and controls, non-clinical, clinical and safety documentation.
Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis
Randomized Phase 2a PRECISION-E2 study designed to evaluate a predefined panel of genes to advance personalized medicine in women's health Randomized Phase 2a PRECISION-E2 study designed to evaluate a predefined panel of genes to advance personalized medicine in women's health
Medicus Pharma receives UAE authorization for Phase 2a endometriosis study of Teverelix
Medicus Pharma (NASDAQ:MDCX) announced that the United Arab Emirates Department of Health – Abu Dhabi (DOH) has granted Investigational New Drug (IND)...
Honeywell upgraded by Bank of America on stronger order trends
Honeywell International Inc (NYSE:HON, XETRA:ALD) was upgraded to ‘Neutral’ from ‘Underperform’ by Bank of America, which raised its price objective to $265...
Medicus Pharma receives FDA clearance to begin registrational SkinJect study for Gorlin syndrome
Medicus Pharma (NASDAQ:MDCX) said the US Food and Drug Administration (FDA) has issued a "Study May Proceed" letter authorizing the company to begin its NDA-enabling Phase 2b registrational study of SkinJect in patients with Gorlin syndrome who develop multiple basal cell carcinomas. The authorization follows the FDA's review of the company's investigational new drug (IND) application for the SKNJCT-005 study and Medicus' response to information requests issued by the agency in June.
Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome
SKNJCT-005 registrational clinical study protocol strengthened through planned implementation of FDA recommendations, including combined clinical and histological clearance endpoints and extended patient follow-up SKNJCT-005 registrational clinical study protocol strengthened through planned implementation of FDA recommendations, including combined clinical and histological clearance endpoints and extended patient follow-up
Nvidia in talks to back OpenAI data center financing with $250B guarantee, WSJ reports
Nvidia Corp (NASDAQ:NVDA, XETRA:NVD) is in talks to provide a roughly $250 billion financial guarantee to support OpenAI's planned data center project in...
Medicus Pharma CEO details Teverelix progress – ICYMI
Medicus Pharma (NASDAQ:MDCX) earlier this week provided an update on its redesigned clinical study for Teverelix, reporting that the revised protocol had received Institutional Review Board approval and had been accepted by the US Food and Drug Administration subject to operational observations. CEO Raza Bokhari told Proactive that the company had acquired the Teverelix development programme through its purchase of UK-based Antev.
Medicus Pharma CEO details Teverelix progress – ICYMI
Medicus Pharma (NASDAQ:MDCX) earlier this week provided an update on its redesigned clinical study for Teverelix, reporting that the revised protocol had...
Medicus Pharma advances Teverelix Phase 2 study after FDA feedback, IRB approval
Medicus Pharma (NASDAQ:MDCX) said it has received US FDA feedback and central Institutional Review Board approval for its optimized Phase 2 study of Teverelix in men following a first episode of acute urinary retention. The redesigned study, designated ANT-2111-02, is expected to enroll approximately 126 patients across the United States and Europe, down from roughly 390 patients contemplated under the company's previously disclosed development plan.
Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention
Regulatory and ethical-review milestones advance a capital-efficient Phase 2 study expected to enroll ~126 patients versus ~390 under the previously disclosed development plan Regulatory and ethical-review milestones advance a capital-efficient Phase 2 study expected to enroll ~126 patients versus ~390 under the previously disclosed development plan
Medicus Pharma advances Teverelix Phase 2 study after FDA feedback, IRB approval
Medicus Pharma (NASDAQ:MDCX) said it has received US FDA feedback and central Institutional Review Board approval for its optimized Phase 2 study of...
Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026
Company's presentation will provide updates on SkinJect® Phase 2b Pivotal Study in patients with Gorlin Syndrome and Teverelix® Groundbreaking PRECISION-E2 Phase 2a Endometriosis Study leveraging the UAE Genome Program Company's presentation will provide updates on SkinJect® Phase 2b Pivotal Study in patients with Gorlin Syndrome and Teverelix® Groundbreaking PRECISION-E2 Phase 2a Endometriosis Study leveraging the UAE Genome Program
Medicus Pharma advances Teverelix in prostate cancer - ICYMI
Medicus Pharma (NASDAQ:MDCX) earlier this week announced the submission of a key European regulatory package designed to support the launch of a Phase 2b clinical study of Teverelix in advanced prostate cancer patients with elevated cardiovascular risk. Speaking with Proactive, chief medical officer Dr Faisal Mehmud said the filing represents an important regulatory milestone for the programme and marks a significant step toward advancing the company's development strategy in an underserved patient population.